Anti-human claudin 18.2 monoclonal antibody and application thereof

1. An anti-human claudin 18.2 monoclonal antibody, having three heavy chain CDRs and three light chain CDRs, wherein

a heavy chain CDR1 is SEQ ID NO: 1, a heavy chain CDR2 is SEQ ID NO: 2, a heavy chain CDR3 is SEQ ID NO: 3, a light chain CDR1 is SEQ ID NO: 4, a light chain CDR2 is SEQ ID NO: 5, and a light chain CDR3 is SEQ ID NO: 6; or

a heavy chain CDR1 is SEQ ID NO: 7, a heavy chain CDR2 is SEQ ID NO: 8, a heavy chain CDR3 is SEQ ID NO: 9, a light chain CDR1 is SEQ ID NO: 10, a light chain CDR2 is SEQ ID NO: 11, a the light chain CDR3 is SEQ ID NO: 12; or

a heavy chain CDR1 is SEQ ID NO: 13, a heavy chain CDR2 is SEQ ID NO: 14, a heavy chain CDR3 is SEQ ID NO: 15, a light chain CDR1 is SEQ ID NO: 16, a light chain CDR2 is SEQ ID NO: 17, a the light chain CDR3 is SEQ ID NO: 18; or

a heavy chain CDR1 is SEQ ID NO: 19, a heavy chain CDR2 is SEQ ID NO: 20, a heavy chain CDR3 is SEQ ID NO: 21, a light chain CDR1 is SEQ ID NO: 22, a light chain CDR2 is SEQ ID NO: 23, and a light chain CDR3 is SEQ ID NO: 24; or

a heavy chain CDR1 is SEQ ID NO: 25, a heavy chain CDR2 is SEQ ID NO: 26, a heavy chain CDR3 is SEQ ID NO: 27, a light chain CDR1 is SEQ ID NO: 28, a light chain CDR2 is SEQ ID NO: 29, a the light chain CDR3 is SEQ ID NO: 30.

2. The antibody according to claim 1 , wherein:

a heavy chain variable region comprises the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3; and

a light chain variable region comprises the light chain CDR1, the light chain CDR2 and the light chain CDR3.

3. The antibody according to claim 2 , wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 79, and the amino acid sequence of the light chain variable region is SEQ ID NO: 80; or the amino acid sequence of the heavy chain variable region is SEQ ID NO: 81, and the amino acid sequence of the light chain variable region is SEQ ID NO: 82; or the amino acid sequence of the heavy chain variable region is SEQ ID NO: 83, and the amino acid sequence of the light chain variable region is SEQ ID NO: 84; or the amino acid sequence of the heavy chain variable region is SEQ ID NO: 85, and the amino acid sequence of the light chain variable region is SEQ ID NO: 86; or the amino acid sequence of the heavy chain variable region is SEQ ID NO: 87, and the amino acid sequence of the light chain variable region is SEQ ID NO: 88.

4. The antibody according to claim 1 , wherein an amino acid sequence of a heavy chain comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3; the heavy chain CDR1 is SEQ ID NO: 1, the heavy chain CDR2 is SEQ ID NO: 2, the heavy chain CDR3 is SEQ ID NO: 3, the light chain CDR1 is SEQ ID NO: 4, the light chain CDR2 is SEQ ID NO: 5, and the light chain CDR3 is SEQ ID NO: 6; or the heavy chain CDR1 is SEQ ID NO: 7, the heavy chain CDR2 is SEQ ID NO: 8, the heavy chain CDR3 is SEQ ID NO: 9, the light chain CDR1 is SEQ ID NO: 10, the light chain CDR2 is SEQ ID NO: 11, and the light chain CDR3 is SEQ ID NO: 12; or the heavy chain CDR1 is SEQ ID NO: 13, the heavy chain CDR2 is SEQ ID NO: 14, the heavy chain CDR3 is SEQ ID NO: 15, the light chain CDR1 is SEQ ID NO: 16, the light chain CDR2 is SEQ ID NO: 17, and the light chain CDR3 is SEQ ID NO: 18; or the heavy chain CDR1 is SEQ ID NO: 19, the heavy chain CDR2 is SEQ ID NO: 20, the heavy chain CDR3 is SEQ ID NO: 21, the light chain CDR1 is SEQ ID NO: 22, the light chain CDR2 is SEQ ID NO: 23, and the light chain CDR3 is SEQ ID NO: 24; or the heavy chain CDR1 is SEQ ID NO: 25, the heavy chain CDR2 is SEQ ID NO: 26, the heavy chain CDR3 is SEQ ID NO: 27, the light chain CDR1 is SEQ ID NO: 28, the light chain CDR2 is SEQ ID NO: 29, and the light chain CDR3 is SEQ ID NO: 30.

5. A host cell, comprising the amino acid sequence of claim 1 .

6. A conjugate, comprising the antibody of claim 1 .

7. A composition, comprising a main component and an auxiliary component, wherein the main component comprises the antibody according to claim 1 or comprises a host cell containing the amino acid sequence of claim 1 , or comprises a conjugate containing the antibody of claim 1 ; the auxiliary component is pharmaceutically acceptable carriers or excipients or other biologically active substances.

8. A kit, comprising the antibody of claim 1 .

9. A nucleic acid molecule, comprising a nucleic acid sequence encoding the three heavy chain CDRs of the anti-human claudin 18.2 monoclonal antibody as described in claim 1 , wherein the three heavy chain CDRs are as follows:

the heavy chain CDR1 is SEQ ID NO: 1, the heavy chain CDR2 is SEQ ID NO: 2 and the heavy chain CDR3 is SEQ ID NO: 3; or

the heavy chain CDR1 is SEQ ID NO: 7, the heavy chain CDR2 is SEQ ID NO: 8 and the heavy chain CDR3 is SEQ ID NO: 9; or

the heavy chain CDR1 is SEQ ID NO: 13, the heavy chain CDR2 is SEQ ID NO: 14 and the heavy chain CDR3 is SEQ ID NO: 15; or

the heavy chain CDR1 is SEQ ID NO: 19, the heavy chain CDR2 is SEQ ID NO: 20 and the heavy chain CDR3 is SEQ ID NO: 21; or

the heavy chain CDR1 is SEQ ID NO: 25, the heavy chain CDR2 is SEQ ID NO: 26 and the heavy chain CDR3 is SEQ ID NO: 27.

10. A vector, comprising the nucleic acid molecule according to claim 9 .

11. A host cell, comprising the nucleic acid molecule of claim 9 , or comprising a vector, the vector comprises the nucleic acid molecule of claim 9 .

12. A composition, comprising a main component and an auxiliary component, wherein the main component comprises the nucleic acid molecule according to claim 9 , or comprises a vector containing the nucleic acid molecule according to claim 9 , or comprises a host cell containing the nucleic acid molecule according to claim 9 , or comprises a host cell containing a vector which containing the nucleic acid molecule according to claim 9 ; the auxiliary component is pharmaceutically acceptable carriers or excipients or other biologically active substances.